GPX4 and renal carcinoma: Silencing GPX4 by shRNA, which leads to a partial knockdown of GPX4, sensitized fibrosarcoma and renal carcinoma cells to a ferroptosis-induced lethality by erastin (63).Consistent with this, the current study revealed a significant decrease of GPX4 expression in both parental and DX-resistant cells after ART treatment, indicating inhibited GPX4 activity accompanied by absent GSH regeneration and therewith accumulation of ROS.